USP5 and plasma cell myeloma: MBZ, a broad-spectrum anthelmintic drug, not only transcriptionally inhibits USP5 expression in myeloma cells 28, but also has efficacy against different types of solid tumors 20-24, which is a repurposed drug for treating tumors.